[HTML][HTML] Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions

R Dadu, ME Cabanillas - Minerva endocrinologica, 2012 - ncbi.nlm.nih.gov
The majority of patients with differentiated thyroid cancer are cured with standard primary
treatments including surgery, radioactive iodine and TSH suppression. A small proportion of …

Drug-induced, factitious, & idiopathic diarrhoea

BP Abraham, JH Sellin - Best practice & research Clinical gastroenterology, 2012 - Elsevier
The aetiology of diarrhoea can often be simple to identify, but in some cases may pose a
challenge. The diagnosis of drug-induced diarrhoea can easily be sorted based on timing of …

[HTML][HTML] GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma

JP Spano, Y Vano, S Vignot, T De La Motte Rouge… - Medical Oncology, 2012 - Springer
Abstract Treatment options for radioiodine resistant metastatic thyroid cancer patients are
limited, and chemotherapy is considered an outdated therapeutic method for differentiated …

Vandetanib for the treatment of metastatic medullary thyroid cancer

N Degrauwe, JA Sosa, S Roman… - Clinical Medicine …, 2012 - journals.sagepub.com
Medullary thyroid cancer (MTC) represents an aggressive form of thyroid malignancy. Some
may occur spontaneously or can be associated with Multiple Endocrine Neoplasia …

New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine‐Refractory Advanced Papillary Thyroid Carcinoma: Literature Review

KP Wong, BHH Lang - Journal of Thyroid Research, 2012 - Wiley Online Library
Although the majority of papillary thyroid carcinoma could be successfully managed by
complete surgical resection alone or resection followed by radioiodine ablation, a small …

Steroids and risk of osteonecrosis in ALL: take a break

MM van den Heuvel-Eibrink, R Pieters - The Lancet Oncology, 2012 - thelancet.com
The results of Leonard Mattano and colleagues' report1 in The Lancet Oncology show that
introduction of scheduled breaks from dexamethasone reduces the risk of osteonecrosis in …

New insight into the treatment of advanced differentiated thyroid cancer

A Safavi, A Vijayasekaran… - Journal of thyroid …, 2012 - Wiley Online Library
The vast majority of patients with differentiated thyroid cancer (DTC) are treated successfully
with surgery and radioactive iodine ablation, yet the treatment of advanced cases is …

Treating advanced radioresistant differentiated thyroid cancer

KC Bible - The Lancet Oncology, 2012 - thelancet.com
Despite a decline in overall mortality from cancer in the USA, thyroid cancer incidence has
more than doubled in the past decade, with an associated rise in mortality. 1, 2 Thyroid …

[PDF][PDF] Cancers différenciés de la thyroïde: prise en charge et place des nouvelles thérapies ciblées.

T Krahenbuhl, L Portmann, S Anchisi - Revue médicale suisse, 2012 - revmed.ch
Dans 25-30% des cancers thyroïdiens médullaires (CTM), il existe une prédisposition
familiale autosomique dominante soit de type MEN 2A (phéochromocytome (PHEO) et …

[HTML][HTML] RET: A multi-faceted gene in human cancer

M Santoro, F Carlomagno… - Endocrinology and …, 2012 - synapse.koreamed.org
REarranged during Transfection (RET) gene encodes a receptor tyrosine kinase and it was
initially discovered as an in vitro transforming gene. For many years, RET has been involved …